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Introduction: We have recently shown that the protein C4.4A is 
induced in early precursor lesions of pulmonary adenocarcinomas 
and squamous cell carcinomas. In the present study, we aimed at ana-
lyzing the impact of C4.4A on the survival of non–small cell lung 
cancer patients and determining whether its unexpected expression 
in adenocarcinomas could be attributed to a specific growth type 
(lepidic, acinar, papillary, micropapillary, solid).
Methods: Sections from the center and periphery of the primary 
tumor, as well as N2-positive lymph node metastases, were stained 
by immunohistochemistry for C4.4A and scored semi-quantitatively 
for intensity and frequency of positive tumor cells.
Results: C4.4A score (intensity × frequency) in the tumor cen-
ter was a highly significant prognostic factor in adenocarcinomas 
(n = 88), both in univariate (p = 0.004; hazard ratio [95% confidence 
interval] = 1.44 [1.12–1.85]) and multivariate statistical analysis 
(p = 0.0005; hazard ratio = 1.65 [1.24–2.19]), demonstrating decreas-
ing survival with increasing score. In contrast, C4.4A did not pro-
vide prognostic information in squamous cell carcinomas (n = 104). 
Pathological stage was significant in both groups. In the adenocarci-
nomas, C4.4A expression was clearly associated with, but a stronger 
prognostic factor than, solid growth.
Conclusions: The present results substantiate the potential value of 
C4.4A as a prognostic marker in pulmonary adenocarcinomas seen 
earlier in a smaller, independent patient cohort. Importantly, we also 
show that C4.4A is a surrogate marker for adenocarcinoma solid 
growth. Recent data suggest that C4.4A is negatively regulated by 
the tumor suppressor liver kinase B1, which is inactivated in some 
adenocarcinomas, providing a possible link to the impact of C4.4A 
on the survival of these patients.
Key Words: Non-small cell lung cancer, LYPD3, Histologic sub-
types of adenocarcinomas, Survival, Biomarker.
(J Thorac Oncol. 2013;8: 152–160)
Lung cancer has for decades caused the highest number of cancer deaths, and 5-year survival rates are still as low 
as 15%.1 It is consequently relevant to search for and char-
acterize new prognostic factors that together with the clini-
cal covariates in current use2–4 would enable more informed 
treatment decisions. Better predictive biomarkers to identify 
patient groups that will respond to new, targeted therapy are 
also necessary to lower the high mortality of lung cancer.
The protein C4.4A, which is a structural homolog to 
the urokinase-type plasminogen activator receptor (uPAR) 
and one of the multidomain members of the Ly6/uPAR/α-
neurotoxin protein family,5,6 is a potential biomarker in 
non-small cell lung cancer (NSCLC).7 C4.4A was originally 
identified as a metastasis-associated protein in a differential 
antigen screen of a rat pancreatic adenocarcinoma cell line.8 
In normal homeostatic tissues, C4.4A is almost exclusively 
expressed in suprabasal layers of stratified squamous epithelia, 
such as the esophagus and oral cavity.9,10 Accordingly, C4.4A 
is absent from the normal healthy lung, in both the alveolar 
and bronchial compartments, but has, however, been detected 
in lung tumor tissue.11,12 When investigating premalignant 
stages of pulmonary adenocarcinomas and squamous cell 
carcinomas (SCCs) in terms of C4.4A expression, we 
have recently demonstrated that C4.4A appears in atypical 
adenomatous hyperplasia (AAH) and basal cell hyperplasia/
squamous metaplasia, which are considered to precede the 
development of the two respective histologic subtypes.13 In an 
immunohistochemical retrospective study of NSCLC patients, 
we have furthermore shown that high expression of C4.4A in 
adenocarcinomas correlates with a very poor patient survival.7 
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The gene encoding C4.4A, designated LYPD3, was recently 
shown to be up-regulated in esophageal cancer cell lines with 
a concomitant loss of the tumor suppressor LKB1, and LYPD3 
knockdown reduced the migratory and invasive potential of 
these cells.14 Inactivation of liver kinase B1 (LKB1), which 
apparently negatively regulates C4.4A expression, has also 
been implicated in NSCLC.15 Interestingly, the pathway 
is predominantly dysregulated in the adenocarcinoma 
subgroup,16,17 and the loss of LKB1 has also been reported in 
a fraction of AAHs.18
In the present study, we have investigated the impact 
of C4.4A on survival in an independent, more contemporary 
(enrollment in 2000–2001 versus 1989–1992), and much 
larger patient material of NSCLC (88 adenocarcinomas/104 
SCCs), as compared with our former prognostic study (40 
adenocarcinomas/56 SCCs). In addition to the primary 
tumors, we have now also included corresponding lymph node 
metastases, inspired by the original identification of C4.4A 
as a metastasis-associated protein,8 as well as by results from 
esophageal SCC, which have revealed a correlation between 
the expression of C4.4A in primary tumors and correspond-
ing local lymph node metastases.9 Importantly, we have fur-
thermore examined the unexpected expression of C4.4A in 
the adenocarcinomas in detail in the different growth patterns 
described for this histologic subtype (lepidic, acinar, papillary, 
micropapillary, and solid), which recently have been shown to 
have a differential influence on patient survival.19,20
MATERIALS AND METHODS
Reagents
A polyclonal anti-C4.4A antibody was produced as out-
lined6 and was subsequently preabsorbed batch-wise against 
immobilized human uPAR to remove trace activities toward 
uPAR domain III (DIII), which served as a purification affin-
ity tag in the original construct used for rabbit immunizations. 
Recombinant secreted human C4.4A (residues 1–274) fused to 
uPAR-DIII was expressed and purified as previously described.21 
Antibody Diluent (#S0809), EnVision+ Anti-Rabbit (#K4003), 
and non-relevant rabbit immunoglobulin (IgG) (#X903) were 
from DakoCytomation (Glostrup, Denmark). Proteinase K 
(#03115879001) was from Roche Diagnostics (Mannheim, 
Germany), VECTOR NovaRED (#SK-4800) from Vector 
Laboratories (Burlingame, CA), and Mayer’s hematoxylin from 
Histolab Products Ab (Gothenburg, Sweden).
Patients 
Two hundred and twenty-nine patients with lung cancer 
were included in the study. They received surgery with cura-
tive intent in 2000 or 2001 at the Thoraxklinik, Heidelberg, 
Germany and were selected consecutively. On the basis of 
the original histopathologic report, the diagnoses comprised 
SCC (n = 104), adenocarcinoma (n = 90), large cell carci-
noma (n = 15), mixed NSCLC without small cell lung can-
cer (SCLC) (n = 11), bronchioloalveolar carcinoma (n = 4), 
SCLC (n = 3), and mixed NSCLC/SCLC (n = 2). We have 
focused our analyses on the two patient groups of SCC and 
adenocarcinoma, whose clinical characteristics are detailed in 
Table 1. For technical reasons, two of the adenocarcinomas 
were excluded. All diagnoses were confirmed by two patholo-
gists (ES-R and ODL). For most patients, two formalin-fixed, 
paraffin-embedded tissue blocks were analyzed, one repre-
senting the periphery and the other the center of the tumor. 
We also had access to a total of 138 blocks with N2-positive 
lymph node metastases from 41 of these patients (27 adeno-
carcinomas and 14 SCCs; 1–8 blocks/patient). Use of the tis-
sue was approved by the Institutional Review Board.
Immunohistochemistry
Sections of 3-5 µm thickness from each tissue block 
were stained immunohistochemically with our polyclonal 
anti-C4.4A antibody as described.6,13 Pretreatment of the 
slides consisted of Proteinase K (10 µg/ml, 15 minutes, 37ºC) 
for antigen retrieval and hydrogen peroxide (1% (v/v), 15 min-
utes, room temperature) to quench endogenous peroxidase 
activity. Incubation of 100 μl of the primary antibody (7.5 µg/
ml) proceeded overnight (20 hours) at 4ºC, followed by 100 
μl Envision+ horseradish peroxidase-labeled anti-rabbit IgG 
for 45 minutes at room temperature. Reaction for C4.4A was 
visualized by a 10-minute development with 200 μl NovaRED 
and counterstaining performed with Mayer’s hematoxylin. 
The slides were stained in nine portions, rigorously keeping 
conditions identical between each round (batches of reagents 
and incubation times). To control for the reproducibility of the 
staining protocol, sections of normal human esophagus and 
amnion, for which the expression patterns of C4.4A are well 
characterized,6,9 were included each time. Negative controls 
consisted of preabsorbing the polyclonal anti-C4.4A antibody 
with a 10-fold molar excess of recombinant C4.4A-DIII pro-
tein6 for at least 30 minutes at room temperature before addi-
tion to the tissue sections,10 staining with 10 μg/ml rabbit IgG 
of irrelevant specificity, Envision-Rabbit IgG + NovaRED 
(i.e., omitting the primary antibody), and NovaRED alone 
(i.e., omitting primary and secondary antibodies).
Evaluation of Immunohistochemical 
C4.4A Staining
All sections were randomized (including controls) for 
a blinded and independent semi-quantitative evaluation of the 
C4.4A staining by two experienced pathologists (ES-R, ODL). 
Each specimen was given scores from 0 to 4 separately for 
intensity (0 = negative; 1 = very weak; 2 = weak; 3 = moder-
ate; 4 = strong staining; Fig. 1A–D) and frequency of C4.4A-
positive tumor cells (0 = 0%; 1 = 0%–25%; 2 = 26%–50%; 3 = 
51%–75%; 4 = >76%), the product of which was used for sta-
tistical analysis. In addition, a lung pathologist (ES-R) analyzed 
the adenocarcinoma samples in more detail by recording muci-
nous and non-mucinous lepidic, acinar, papillary, micropapil-
lary, and solid components representing at least 10% of tumor 
tissue in each sample, as well as quantifying the corresponding 
C4.4A expression in these different growth patterns.
Statistics
Agreement between the two observers was assessed by 
Kappa statistics, Wilcoxon signed-rank tests, and Spearman 
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rank correlations. Descriptive statistics for C4.4A scores are 
presented by the median and range, and the Spearman rank 
correlation was used as a measure of association between 
parameters. C4.4A was scored by the actual value for the 
periphery (PP; n = 182) and the center (PC; n = 186). Estimates 
of survival probabilities were done using the Kaplan–Meier 
method, and differences between strata were tested by the 
log rank statistic. The C4.4A scores were grouped using their 
respective tertiles as cut-points for the Kaplan–Meier survival 
curves. Multivariate overall survival analysis of C4.4A and the 
clinical covariates was performed with the Cox proportional 
hazards model. Separate analyses were done for each histology. 
The assumptions of the model, that is, the proportionality 
assumption and the functional form of PP and PC, were verified 
using the Schoenfeld and Martingale residuals. The analyses 
included only patients in tumor, node, metastasis stages 
I to IIIA. In addition to C4.4A scores (PP and PC) and the 
most frequent growth patterns (solid and acinar), the clinical 
covariates pathological stage, Eastern Cooperative Oncology 
Group performance status, sex, age, and treatment (adjuvant 
radiotherapy and/or chemotherapy versus operation only, for 
stages II and III only) were assessed. A final model for each 
histology was selected including only statistically significant 
covariates. The final models were validated using cross-
validation methods as described in Harrell et al.22 Results are 
presented by hazard ratio (HR) with 95% confidence intervals 
(CIs). For the C4.4A levels, HR is presented for a difference 
of four score points. p values less than 5% are considered 
significant. Statistical calculations were done using the SAS 
statistical software (version 9.2, SAS Institute, Cary, NC).
RESULTS
The Immunohistochemical Protocol for 
Quantifying C4.4A Levels is Specific and Robust
As the NSCLC tissue sections were stained for C4.4A 
in nine batches, we performed control experiments to ensure 
that an unbiased survival analysis based on semi-quantitative 
evaluation of C4.4A expression could be performed. Identical 
TABLE 1.  Patient Characteristics
Adenocarcinoma Squamous cell carcinoma
Variable n (%) n (%)
Total 88 104
Sex Female 34 (39) 15 (14)
Male 54 (61) 89 (86)
Performance status 0 34 (39) 39 (38)
1 40 (45) 59 (57)
2 9 (10) 5 (5)
Missing 5 (6) 1 (1)
Pathological stage IA 19 (22) 8 (8)
IB 14 (16) 28 (27)
IIA 5 (6) 7 (7)
IIB 14 (16) 33 (32)
IIIA 24 (27) 19 (18)
IIIB 8 (9) 7 (7)
IV 4 (5) 2 (2)
Cause of death Tumor 31 (35) 37 (36)
Tumor-unrelated 4 (5) 4 (4)
Unknown 16 (18) 13 (13)
Alive 37 (42) 50 (48)
Treatment Operation only 58 (66) 87 (84)
Operation + radiotherapy 19 (22) 11 (11)
Operation + chemotherapy 2 (2) 3 (3)
Operation + radiotherapy + chemotherapy 9 (10) 3 (3)
Procedure Lobectomy 69 (78) 65 (63)
Pneumonectomy 12 (14) 28 (27)
Other 7 (8) 11 (11)
Tumor site Upper lobe 50 (57) 68 (65)
Lower lobe 30 (34) 30 (29)
Other 8 (9) 6 (6)
Age (yrs) Median 61.3 61.5
Range 35.4–82.2 43.8–78.8
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results were obtained for positive controls included in every 
round, and negative controls were devoid of C4.4A staining 
(Supplementary Figure S1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A380).
Statistical evaluation of the degree of agreement 
between the two pathologists performing the scoring of 
expression levels of C4.4A in adenocarcinoma and SCC (n = 
192) revealed kappa values (95% CI) of 0.65 (0.58–0.71) and 
0.56 (0.50–0.62) for the product scores (intensity × frequency) 
at the tumor periphery and center, respectively. The corre-
sponding kappa value for the evaluation of N2-positive lymph 
node metastases stained for C4.4A was 0.63 (0.54–0.71). The 
Spearman correlations (0.84 in the PP and 0.87 in the PC of 
primary tumors) and the mutual agreements were substantial, 
and the mean score between the two observers was therefore 
chosen for subsequent statistical analysis of the study material.
Taken together, this demonstrates the reproducibility 
and specificity of C4.4A immunohistochemistry, as well as 
the robustness of the scoring system.
C4.4A is a Prognostic Factor in 
Adenocarcinomas but not in SCCs
The levels of C4.4A expression in SCC and 
adenocarcinoma differ substantially, with much higher levels 
FIGURE 1.  Scoring of C4.4A. A–D 
illustrate the staining levels in non–
small cell lung cancer on which the 
scoring of C4.4A was based, with 
intensities gradually increasing from 
very weak (A), weak (B), moder-
ate (C), to strong (D) (Scale bars: 
50 μm). The correlation between 
C4.4A scores at the tumor center 
and periphery is presented as scat-
ter plots for AC and SCC in E and 
F, respectively. G and H depict box 
plots of center and periphery scores 
of C4.4A, delimiting the values for 
upper and lower quartiles, as divided 
by pathological stage I–IV (AC to 
the left and SCC to the right). The 
median is shown as a line within each 
box, and the dots represent outliers. 
AC, adenocarcinoma; SCC, squa-
mous cell carcinoma.
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in the former (median, 8) than in the latter (median, 1 in the 
PC and 2 in the PP) (Supplementary Table S1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A380). Statistical 
data analysis was therefore systematically stratified for 
histology. Center and periphery of the tumor were similarly 
evaluated separately.
Univariate analysis of overall survival is shown in 
Table 2 and Supplementary Table S2 (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A380) for the two histo-
logic subtypes. In the adenocarcinoma group, there was a clear 
significance of C4.4A center score (PC), with an HR of 1.44 
(95% CI = 1.12–1.85) and a p value of 0.004 (pr. 4-unit dif-
ference in score), and of pathological stage (p = 0.0002). For 
SCC, only pathological stage was significant (p = 0.017), that 
is, there was no association between C4.4A score and survival 
in this histologic group. HRs for stage are indicated in the 
tables. The difference in prognostic significance of C4.4A in 
adenocarcinoma and SCC by univariate analysis is graphically 
illustrated by the Kaplan–Meier estimates generated for PC, 
grouped by their respective tertiles (Fig. 2). For the adenocar-
cinoma patients, increasing levels of C4.4A were associated 
with poor patient survival (p = 0.002). The Spearman correla-
tions between C4.4A scores at the center and periphery were 
high for both adenocarcinomas (r = 0.75) and SCCs (r = 0.69) 
(Fig. 1E and F), and the corresponding Kaplan–Meier analysis 
using the C4.4A periphery score yielded similar curves (not 
shown). Importantly, these results validate our earlier observa-
tions in a smaller, independent patient cohort.7
High Expression of C4.4A in Adenocarcinomas 
Correlates with Solid Growth Pattern
As pulmonary adenocarcinomas do not originate from 
squamous epithelium, where C4.4A expression normally 
is found,10 we would not expect C4.4A to be present at all 
in these tissues. Although many of the samples indeed were 
negative for C4.4A, a fraction, however, was found to express 
the protein. To evaluate whether this could be attributed to one 
of the specific growth patterns seen in this histologic subtype, 
we quantified C4.4A reactivity separately in mucinous and 
non-mucinous lepidic, acinar, papillary, micropapillary, 
and solid components of all adenocarcinoma specimens. 
As evident from the descriptive statistics in Supplementary 
Table S1 (Supplemental Digital Content 1, http://links.lww.
com/JTO/A380) and the immunohistochemical pictures in 
Figure 3, C4.4A expression was much more pronounced in 
the solid than any of the other growth types, with the median 
C4.4A score being significantly higher in specimens with 
some solid component than in those with no solid component 
(4 and 0, respectively; p = 0.0002 in the center and p = 0.012 
in the periphery). There was thus a clear association between 
C4.4A expression and adenocarcinoma solid growth pattern. 
In contrast, C4.4A score was significantly associated neither 
with age, sex, or performance status (data not shown), nor with 
pathological stage, which is illustrated for adenocarcinoma 
and SCC in Figure 1G and H.
C4.4A is a Stronger Prognostic 
Factor than Solid Growth
We next took growth pattern into account in a more 
detailed analysis of survival in 75 adenocarcinoma patients 
(stages I–IIIA). Because of a large heterogeneity within 
each sample (Supplementary Table 3, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A380), we focused on 
the two most common types seen in the present study mate-
rial, that is, solid and acinar. A specimen was considered solid/
acinar if the given growth type represented at least 10% of the 
tumor tissue examined.
By univariate analysis, patients with solid growth in the 
tumor center had a poorer survival (p = 0.035), in accordance 
with other studies,23,24 whereas no association could be dem-
onstrated for acinar growth (p = 0.21). The proportion of solid 
component (some, predominant, or pure solid growth) did not 
influence the analysis, that is, the mere fact of having some 
solid component was indicative of a poor prognosis.
In a multivariate analysis including only C4.4A, solid 
growth and their interaction, all these factors were signifi-
cant in the tumor center (p values of 0.006, 0.043, and 0.037, 
respectively), but not in the periphery (p values of 0.76, 0.32, 
and 0.85, respectively). The interaction between C4.4A and 
solid growth, however, was no longer significant (p = 0.37) 
when the multivariate analysis was extended to include C4.4A 
scores (PP and PC), growth pattern (solid and acinar), the 
TABLE 2.  Analysis of Overall Survival (Adenocarcinoma)
Covariate
Univariate Multivariate
Hazard Ratio (95% CI) p Hazard Ratio (95% CI) p
Stage IIA + B vs. stage IA + B 0.88 (0.36–2.17)
0.0002
0.69 (0.27–1.76)
<0.0001
Stage IIIA vs. stage IA + B 3.64 (1.82–7.29) 4.74 (2.26–9.95)
Performance status (1 + 2 vs. 0) 0.71 (0.37–1.37) 0.30 0.77b
Sex (female vs. male) 1.03 (0.55–1.93) 0.94 0.32b
Age (per 10 yrs) 1.22 (0.91–1.63) 0.19 0.45b
Treatment (adjuvant vs. nonea) 0.72 (0.27–1.91) 0.50 0.63b
C4.4A center score (pr. 4 units) 1.44 (1.12–1.85) 0.004 1.65 (1.24–2.19) 0.0005
C4.4A periphery score (pr. 4 units) 1.16 (0.86–1.56) 0.33 0.89b
The analysis was performed on patients in stages I through IIIA, thus excluding 12 patients in stages IIIB and IV.
aFor stages II and III only and adjusted for stage.
bp value to include covariate in the model.
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C4.4A/solid interaction, pathological stage, performance sta-
tus, sex, age, and treatment, where the only significant inde-
pendent factors were pathological stage and PC (p = 0.0005), 
with an HR of 1.65 (95% CI 1.24–2.19), adjusted for stage 
(p < 0.0001) (Table 2). Significant interactions could not be 
detected between these two parameters. The cross-validation 
of this final model demonstrated that the selection of stage 
and PC was very robust and suggested that the growth pat-
tern is not an independent predictor. Stage was thus a stronger 
predictor than solid growth. If C4.4A was removed from the 
model, solid pattern remained non-significant, meaning that 
even though there was an interaction between solid growth 
FIGURE 2.  C4.4A provides prognostic information in 
adenocarcinoma but not squamous cell carcinoma patients. 
Correlation of C4.4A scores with survival of adenocarci-
noma and squamous cell carcinoma patients is illustrated 
by Kaplan–Meier estimates (tumor center score) in A and 
B, respectively, grouped by their respective tertiles (in red, 
blue, and green). The number of events (death of all causes), 
patients at risk at 0, 24, 48, and 72 months, and range of 
C4.4A scores are indicated below the axis for each tertile.
FIGURE 3.  C4.4A is primarily expressed in the solid compo-
nent of pulmonary adenocarcinomas. Specimens of pul-
monary adenocarcinoma were stained with our polyclonal 
anti-C4.4A antibody and developed with NovaRED chromo-
gen. As shown in the examples of solid, acinar, and papillary 
growth patterns in A, B, and C, respectively, most C4.4A 
reactivity is found in solid components. Scale bars: 100 μm.
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and C4.4A, the latter was a stronger predictor than the former 
in the model. If PC was removed from the model, PP became 
significant (p = 0.044; HR = 1.45 [1.01–2.07]).
In the corresponding multivariate analysis of SCC 
patients, only stage was significant (p = 0.009), and the p 
value to include PC in the model was 0.82 (Supplementary 
Table S2, Supplemental Digital Content 1, http://links.lww.
com/JTO/A380).
C4.4A Expression in Primary Tumors 
is Recapitulated in Corresponding 
Lymph Node Metastases
Comparison of primary tumors and corresponding 
lymph node metastases revealed a relatively high correlation 
in their C4.4A expression (Spearman correlations ~ 0.6–0.7). 
Similarly, there was a relatively high correlation between the 
C4.4A scores in different metastases from the same patient, 
of which there were up to eight. It thus seems that the C4.4A 
expression pattern of the primary tumor is recapitulated in 
the metastasis. Interestingly, in seven specimens from two 
patients, the metastases were of adenocarcinoma histology 
with signet ring cells, normally implying poor differentiation 
and poor survival,25 and these were strongly C4.4A-positive. 
Both of these patients had a primary tumor with a predominant 
solid growth pattern and indeed a poor survival.
DISCUSSION
In the present study, we demonstrate that the novel bio-
marker C4.4A is a significant, independent prognostic factor 
in pulmonary adenocarcinoma, although it does not provide 
any information on the survival of SCC patients. We find 
comparable expression patterns in primary tumors and cor-
responding lymph node metastases, further substantiating that 
induction of C4.4A expression is an early event in the progres-
sion to both adenocarcinoma and SCC, as recently revealed 
by our study on precursor lesions of NSCLC.13 The differen-
tial prognostic impact in the two histologic subtypes suggests, 
however, that C4.4A plays distinct roles in the development of 
these two malignancies.
In the case of SCC, the onset of C4.4A expression is 
seen already in basal cell hyperplasia of the bronchial epi-
thelium, that is, at a stage even preceding the premalignant 
lesions,13 indicating that C4.4A is a very early marker of 
squamous differentiation. This view is also supported by its 
first appearance in murine embryogenesis coinciding with the 
differentiation-specific cytokeratin 1010 and is well in line with 
normal C4.4A expression being confined to squamous epithe-
lium.6,9,10 As this normally is strictly regulated, as convinc-
ingly illustrated at squamo-columnar transition zones, where 
intense C4.4A expression at the squamous side abruptly ter-
minates in the columnar epithelium,10 C4.4A appearance in 
the alveolar compartment is, however, an unexpected event 
per se. Our detailed analysis of the different adenocarcinoma 
growth patterns revealed that this C4.4A expression in adeno-
carcinomas tightly correlates with solid growth.
Together with our observation of C4.4A positivity in a 
fraction of AAH lesions, this provides the intriguing possi-
bility that these C4.4A-positive AAH lesions may eventually 
develop into C4.4A-positive solid adenocarcinomas, with an 
ensuing severely compromised patient survival. This remains 
to be established, however, for example, by the use of mouse 
models, as it is presently unclear whether AAH can progress all 
the way to overt solid adenocarcinoma.19,26,27 The interrelation-
ship between the acinar, papillary, micropapillary, and solid 
components is, furthermore, not well defined, for example, 
with regard to whether they reflect distinct genotypes or have 
the same cell of origin, such as the proposed bronchioalveolar 
stem cell located at the bronchioalveolar duct junction.28 Gene 
expression profiling suggests that adenocarcinomas indeed dif-
fer according to morphology, invasiveness, and mutations.29,30 
This diversity is also reflected by differences in patient sur-
vival according to predominant subtype, where non-mucinous 
lepidic and solid/micropapillary growth confer the best and 
worst survival, respectively.23,24 The high heterogeneity within 
adenocarcinomas could point to the existence of differentiation 
pathways not yet described for the progression from AAH to 
adenocarcinoma,31 linked to other oncogenic drivers than the 
epidermal growth factor receptor and KRAS signalling path-
ways.19,27,32 With a view to the above, C4.4A might be impli-
cated in or reporting on the activity of such a novel pathway. 
Because C4.4A normally is confined to squamous epithelium, 
C4.4A can possibly identify adenocarcinoma tumors in a dif-
ferentiation state similar to an SCC phenotype. In line with 
this, a recent study reported on adenocarcinomas, of mainly the 
solid pattern with signet-ring cell morphology, coexpressing 
thyroid transcription factor-1  and p63, which are markers of 
adenocarcinomas and SCCs, respectively.33
The unexpected presence of C4.4A in adenocarcinoma 
could be caused by disruption of the normal stringent con-
trol of its expression, and subsequent erroneous activation of 
a pathway with a putatively higher malignant potential. This 
could, for example, involve the tumor suppressor LKB1, which 
recently has been suggested as a negative regulator of C4.4A.14 
The fact that in lung cancer, LKB1 alterations are found pri-
marily in adenocarcinomas,16,17 and often in poorly differenti-
ated cases,34 one of the characteristics of solid growth, lends 
support to this hypothesis. Loss of LKB1 expression has also 
been demonstrated in AAH lesions.18
Our ability to reproduce earlier findings in a completely 
independent patient cohort7 demonstrates the robustness of 
the association between C4.4A levels and adenocarcinoma 
patient survival, which in part can be attributed to an unam-
biguous, easily quantifiable immunohistochemical staining of 
C4.4A, with good interobserver agreement. Despite the obvi-
ous association between C4.4A expression and solid growth, 
multivariate analysis shows that C4.4A has a higher prog-
nostic impact than solid growth. Because C4.4A behaves as 
a continuous variable, that is, the higher C4.4A, the poorer 
the patient survival, and according to the present data can 
yield prognostic information additional to that given by solid 
growth,23,24 it might, in conjunction with solid growth and other 
relevant markers, be used to refine the stratification of early-
stage adenocarcinoma patients according to survival. This is 
important with regard to clinical decision making on adjuvant 
therapy, where markers are needed for the identification of 
stage I patients who recur and therefore could benefit from 
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such treatment, and stage II patients who experience curative 
surgery and should be spared the adverse effects of additional 
chemo/radiation therapy.35 LYPD3, the gene encoding C4.4A, 
has actually recently been selected as one of a 91-gene quanti-
tative real-time polymerase chain reaction–based classifier for 
predicting survival of lung adenocarcinoma patients.36 It has 
also been reported that adenocarcinoma patients with a pre-
dominant solid growth pattern seem to benefit from adjuvant 
radiotherapy.20
Although the tumor, node, metastasis classification still 
represents the standard tool for the management of NSCLC 
patients, biological and molecular aspects of a tumor are being 
exploited to improve and individualize outcome prediction 
and consequent treatment decisions,3 as exemplified by the 
dependence of tyrosine kinase inhibitor response on EGFR 
mutations.37–39 In terms of its possible negative regulation by 
LKB1,14 it is tempting to speculate that C4.4A could be used 
as a marker for the efficacy of treatment targeting the LKB1 
pathway in adenocarcinomas. This includes mammalian 
target of rapamycin inhibition, which is being investigated 
in ongoing clinical trials.40,41 We are currently aiming at 
exploring a possible link between C4.4A positivity and LKB1 
deficiency in lung cancer.
In conclusion, we have shown for the first time that the 
surprising expression of C4.4A in pulmonary adenocarcino-
mas is a surrogate marker for solid growth, and this correlates 
with a poor patient survival. By delineating the function of 
C4.4A, it will be clarified whether this protein is involved in 
a mechanism that could be targeted therapeutically at the cell 
surface of adenocarcinomas with a solid component.
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